AAPL340.08+3.17 (+0.94%) ▲|ABBV263.20+6.29 (+2.45%) ▲|ABT107.27+2.78 (+2.66%) ▲|ACN164.66+10.60 (+6.88%) ▲|ADBE249.18+11.43 (+4.81%) ▲|AMAT476.46-40.43 (-7.82%) ▼|AMD454.62-40.33 (-8.15%) ▼|AMGN393.10+16.84 (+4.48%) ▲|AMT171.50+4.76 (+2.85%) ▲|AMZN230.86-0.53 (-0.23%) ▼|AVGO380.91-2.31 (-0.60%) ▼|AXP336.63+1.24 (+0.37%) ▲|BA221.56+10.06 (+4.76%) ▲|BAC62.62+0.49 (+0.79%) ▲|BKNG199.31+12.52 (+6.70%) ▲|BLK1,097.55+35.41 (+3.33%) ▲|BMY63.60+1.04 (+1.66%) ▲|BNY156.49-1.28 (-0.81%) ▼|BRK-B512.37+15.19 (+3.06%) ▲|C132.47-0.63 (-0.47%) ▼|CAT840.85-32.43 (-3.71%) ▼|CL92.73+0.75 (+0.82%) ▲|CMCSA24.19+1.39 (+6.10%) ▲|COF212.41+5.36 (+2.59%) ▲|COP114.10-1.48 (-1.28%) ▼|COST966.58+15.00 (+1.58%) ▲|CRM181.50+7.90 (+4.55%) ▲|CSCO115.58+1.01 (+0.88%) ▲|CVS109.34+2.27 (+2.12%) ▲|CVX187.58-2.42 (-1.27%) ▼|DE639.84+14.82 (+2.37%) ▲|DHR199.05+2.55 (+1.30%) ▲|DIS98.89+2.24 (+2.32%) ▲|DUK129.24+0.41 (+0.32%) ▲|EMR151.81+2.51 (+1.68%) ▲|FDX312.64+1.85 (+0.60%) ▲|GD393.19+4.05 (+1.04%) ▲|GE363.59+1.98 (+0.55%) ▲|GEV943.38-53.19 (-5.34%) ▼|GILD134.32+3.80 (+2.91%) ▲|GM90.30+3.26 (+3.75%) ▲|GOOG332.60+6.03 (+1.85%) ▲|GOOGL333.71+7.15 (+2.19%) ▲|GS1,033.34-14.89 (-1.42%) ▼|HD344.47+8.38 (+2.49%) ▲|HON247.05+1.30 (+0.53%) ▲|IBM227.55+11.27 (+5.21%) ▲|INTC86.30-5.37 (-5.86%) ▼|INTU312.99+9.08 (+2.99%) ▲|ISRG361.80+4.97 (+1.39%) ▲|JNJ266.73+0.78 (+0.29%) ▲|JPM357.31+1.11 (+0.31%) ▲|KO88.27+4.20 (+5.00%) ▲|LIN511.18+4.16 (+0.82%) ▲|LLY1,220.66+23.13 (+1.93%) ▲|LMT581.31+1.31 (+0.23%) ▲|LOW218.24+6.69 (+3.16%) ▲|LRCX269.61-22.00 (-7.54%) ▼|MA562.75+11.04 (+2.00%) ▲|MCD273.02+2.35 (+0.87%) ▲|MDLZ62.48+1.81 (+2.98%) ▲|MDT86.88+2.66 (+3.16%) ▲|META593.41-0.46 (-0.08%) ▼|MMM182.48+4.25 (+2.38%) ▲|MO74.82+1.93 (+2.65%) ▲|MRK131.82+1.06 (+0.81%) ▲|MS211.58-2.98 (-1.39%) ▼|MSFT393.35+4.25 (+1.09%) ▲|MU820.53-79.67 (-8.85%) ▼|NEE89.28+0.45 (+0.51%) ▲|NFLX72.39+1.99 (+2.83%) ▲|NKE43.05+0.91 (+2.16%) ▲|NOW110.62+5.06 (+4.79%) ▲|NVDA197.01+0.50 (+0.25%) ▲|ORCL119.96+0.06 (+0.05%) ▲|PEP142.86+3.07 (+2.20%) ▲|PFE25.25+0.58 (+2.35%) ▲|PG148.88+0.25 (+0.17%) ▲|PLTR123.53-8.00 (-6.08%) ▼|PM200.17+4.51 (+2.31%) ▲|QCOM162.88-7.16 (-4.21%) ▼|RTX218.58+0.16 (+0.07%) ▲|SBUX103.10-0.55 (-0.53%) ▼|SCHW105.97+1.79 (+1.72%) ▲|SO96.78+0.30 (+0.31%) ▲|SPG236.70+5.03 (+2.17%) ▲|T24.66+0.24 (+0.98%) ▲|TMO576.41+16.88 (+3.02%) ▲|TMUS182.39+5.18 (+2.92%) ▲|TSLA307.44-1.78 (-0.58%) ▼|TXN277.07-2.34 (-0.84%) ▼|UBER70.74+2.56 (+3.75%) ▲|UNH428.79+11.15 (+2.67%) ▲|UNP294.45-4.85 (-1.62%) ▼|UPS105.53-7.42 (-6.57%) ▼|USB64.43+0.94 (+1.48%) ▲|V366.59+4.06 (+1.12%) ▲|VZ48.19+0.87 (+1.84%) ▲|WFC86.87-0.40 (-0.46%) ▼|WMT113.10+1.36 (+1.22%) ▲|XOM153.04-1.73 (-1.12%) ▼|AAPL340.08+3.17 (+0.94%) ▲|ABBV263.20+6.29 (+2.45%) ▲|ABT107.27+2.78 (+2.66%) ▲|ACN164.66+10.60 (+6.88%) ▲|ADBE249.18+11.43 (+4.81%) ▲|AMAT476.46-40.43 (-7.82%) ▼|AMD454.62-40.33 (-8.15%) ▼|AMGN393.10+16.84 (+4.48%) ▲|AMT171.50+4.76 (+2.85%) ▲|AMZN230.86-0.53 (-0.23%) ▼|AVGO380.91-2.31 (-0.60%) ▼|AXP336.63+1.24 (+0.37%) ▲|BA221.56+10.06 (+4.76%) ▲|BAC62.62+0.49 (+0.79%) ▲|BKNG199.31+12.52 (+6.70%) ▲|BLK1,097.55+35.41 (+3.33%) ▲|BMY63.60+1.04 (+1.66%) ▲|BNY156.49-1.28 (-0.81%) ▼|BRK-B512.37+15.19 (+3.06%) ▲|C132.47-0.63 (-0.47%) ▼|CAT840.85-32.43 (-3.71%) ▼|CL92.73+0.75 (+0.82%) ▲|CMCSA24.19+1.39 (+6.10%) ▲|COF212.41+5.36 (+2.59%) ▲|COP114.10-1.48 (-1.28%) ▼|COST966.58+15.00 (+1.58%) ▲|CRM181.50+7.90 (+4.55%) ▲|CSCO115.58+1.01 (+0.88%) ▲|CVS109.34+2.27 (+2.12%) ▲|CVX187.58-2.42 (-1.27%) ▼|DE639.84+14.82 (+2.37%) ▲|DHR199.05+2.55 (+1.30%) ▲|DIS98.89+2.24 (+2.32%) ▲|DUK129.24+0.41 (+0.32%) ▲|EMR151.81+2.51 (+1.68%) ▲|FDX312.64+1.85 (+0.60%) ▲|GD393.19+4.05 (+1.04%) ▲|GE363.59+1.98 (+0.55%) ▲|GEV943.38-53.19 (-5.34%) ▼|GILD134.32+3.80 (+2.91%) ▲|GM90.30+3.26 (+3.75%) ▲|GOOG332.60+6.03 (+1.85%) ▲|GOOGL333.71+7.15 (+2.19%) ▲|GS1,033.34-14.89 (-1.42%) ▼|HD344.47+8.38 (+2.49%) ▲|HON247.05+1.30 (+0.53%) ▲|IBM227.55+11.27 (+5.21%) ▲|INTC86.30-5.37 (-5.86%) ▼|INTU312.99+9.08 (+2.99%) ▲|ISRG361.80+4.97 (+1.39%) ▲|JNJ266.73+0.78 (+0.29%) ▲|JPM357.31+1.11 (+0.31%) ▲|KO88.27+4.20 (+5.00%) ▲|LIN511.18+4.16 (+0.82%) ▲|LLY1,220.66+23.13 (+1.93%) ▲|LMT581.31+1.31 (+0.23%) ▲|LOW218.24+6.69 (+3.16%) ▲|LRCX269.61-22.00 (-7.54%) ▼|MA562.75+11.04 (+2.00%) ▲|MCD273.02+2.35 (+0.87%) ▲|MDLZ62.48+1.81 (+2.98%) ▲|MDT86.88+2.66 (+3.16%) ▲|META593.41-0.46 (-0.08%) ▼|MMM182.48+4.25 (+2.38%) ▲|MO74.82+1.93 (+2.65%) ▲|MRK131.82+1.06 (+0.81%) ▲|MS211.58-2.98 (-1.39%) ▼|MSFT393.35+4.25 (+1.09%) ▲|MU820.53-79.67 (-8.85%) ▼|NEE89.28+0.45 (+0.51%) ▲|NFLX72.39+1.99 (+2.83%) ▲|NKE43.05+0.91 (+2.16%) ▲|NOW110.62+5.06 (+4.79%) ▲|NVDA197.01+0.50 (+0.25%) ▲|ORCL119.96+0.06 (+0.05%) ▲|PEP142.86+3.07 (+2.20%) ▲|PFE25.25+0.58 (+2.35%) ▲|PG148.88+0.25 (+0.17%) ▲|PLTR123.53-8.00 (-6.08%) ▼|PM200.17+4.51 (+2.31%) ▲|QCOM162.88-7.16 (-4.21%) ▼|RTX218.58+0.16 (+0.07%) ▲|SBUX103.10-0.55 (-0.53%) ▼|SCHW105.97+1.79 (+1.72%) ▲|SO96.78+0.30 (+0.31%) ▲|SPG236.70+5.03 (+2.17%) ▲|T24.66+0.24 (+0.98%) ▲|TMO576.41+16.88 (+3.02%) ▲|TMUS182.39+5.18 (+2.92%) ▲|TSLA307.44-1.78 (-0.58%) ▼|TXN277.07-2.34 (-0.84%) ▼|UBER70.74+2.56 (+3.75%) ▲|UNH428.79+11.15 (+2.67%) ▲|UNP294.45-4.85 (-1.62%) ▼|UPS105.53-7.42 (-6.57%) ▼|USB64.43+0.94 (+1.48%) ▲|V366.59+4.06 (+1.12%) ▲|VZ48.19+0.87 (+1.84%) ▲|WFC86.87-0.40 (-0.46%) ▼|WMT113.10+1.36 (+1.22%) ▲|XOM153.04-1.73 (-1.12%) ▼|
24 C
New York
Wednesday, July 29, 2026

Tag: pharmaceutical

newssourceFORcompanyinformationcontent1releasesmarket

Teva Releases Q2 2026 Aide Memoire

TEL AVIV, Israel, June 18, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that its Q2 2026 Aide Memoire is available on the “Investors” page on its website.

Teva Submits NDA for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Tourette Syndrome

TEL AVIV, Israel, June 18, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for ecopipam, a first-in-class investigational therapy for the treatment of pediatric Tourette syndrome.

CenExel Appoints Bethany Sensenig as Chief Financial Officer

DRAPER, Utah, June 18, 2026 /PRNewswire/ -- CenExel, a leading, wholly owned clinical research site network, announced today the expansion of its leadership team...

KRTL Holding Group Announces RAYEL and PERIKO Coca-Derived Extract Platform for Beverage and Pharmaceutical API Development

KRTL announces RAYEL and PERIKO, a coca-derived beverage and pharmaceutical development platform supported by KRTL subsidiaries and CIQ.

Resilience Announces Relocation of West Coast Headquarters to Ohio and Expansion of Sterile Manufacturing Capabilities

BLUE ASH, Ohio, June 18, 2026 (GLOBE NEWSWIRE) -- Resilience, along with Ohio Governor Mike DeWine, JobsOhio, the City of Blue Ash, and REDI Cincinnati, today announced the relocation of Resilience’s corporate headquarters from San Diego, California to Blue Ash, Ohio, a northern suburb of Cincinnati. Resilience is a leading biomanufacturing contract and development manufacturing organization (CDMO) dedicated to broadening access to complex medicines, with a large drug product manufacturing facility in West Chester, Ohio. This move strengthens the company’s operational footprint in the state, and reinforces Ohio’s position as a growing hub for pharmaceutical and sterile manufacturing innovation.

SK pharmteco Announces Strategic Collaboration with Orphan Therapeutics Accelerator for the Development and Manufacturing of Rare Disease Therapies

SK pharmteco announces a collaborative agreement with the Orphan Therapeutics Accelerator (OTXL) to support the advancement of novel therapeutic programs.

F2G and Shionogi Announce Positive Topline Results From Global Phase 3 OASIS Study Evaluating Oral Olorofim Versus AmBisome® Followed by Standard of Care in...


MANCHESTER, United Kingdom and OSAKA, Japan, June 18, 2026 (GLOBE NEWSWIRE) -- F2G Ltd and Shionogi & Co., Ltd (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D) (“Shionogi”) today announced positive topline results from the global Phase 3 OASIS study (NCT05101187), comparing the investigational oral antifungal drug olorofim versus AmBisome® (liposomal amphotericin B for injection) followed by standard of care (SOC) in patients with invasive aspergillosis whose infection is either refractory to or unsuitable for azole therapy.

AI-Powered Analysis by HistoIndex Reveals Robust Liver Fibrosis Improvement with D&D Pharmatech’s Zabopegdutide in Phase 2 MASH Trial

SINGAPORE and SEOUL, South Korea, June 18, 2026 /PRNewswire/ -- HistoIndex, a leader in AI-powered digital pathology solutions for fibrosis assessment, and D&D Pharmatech,...

ZYUS Life Sciences Corporation Announces Closing of Third Tranche of Secured Loan Financing

/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/SASKATOON, SK, June 17, 2026 /CNW/ - ZYUS Life Sciences Corporation...

MediPharm Labs Announces Voting Results from the 2026 Annual and Special Meeting of Shareholders

MediPharm Labs announces the results of matters voted on at its annual and special meeting of shareholders held today.

New Mexico Community College Demonstrates Groundbreaking Quantum Technician Training Model with Colleges Across the U.S.

Central New Mexico Community College launched the first quantum technician training program of its kind in the country in fall 2025 to support workforce...

Specialty Silica Market to Reach USD 14.1 Billion by 2036, Driven by Green Tire Innovation and High-Purity Industrial Applications | Future Market Insights

NEWARK, Del., June 17, 2026 /PRNewswire/ -- The global Specialty Silica Market is witnessing significant momentum as demand accelerates across automotive, electronics, personal care, pharmaceuticals, and...

Specialty Silica Market to Reach USD 14.1 Billion by 2036, Driven by Green Tire Innovation and High-Purity Industrial Applications | Future Market Insights

NEWARK, Del., June 17, 2026 /PRNewswire/ -- The global Specialty Silica Market is witnessing significant momentum as demand accelerates across automotive, electronics, personal care, pharmaceuticals, and...

$GRAL Fraud Notice: GRAIL, Inc. Accused of Securities Fraud over Trial Results in Filed Class Action Lawsuit – Investors Notified to Contact BFA Law

GRAIL, Inc. Accused of Securities Fraud over Trial Results in Filed Class Action Lawsuit – Investors Notified to Contact BFA Law

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsPharmaceutical

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers